
We claim:

1. Use of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol (Compound 1) having the structure:



,

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of abnormal cell growth in a subject, wherein a therapeutically effective amount of the medicament is to be administered to said subject no more than once per day.

2. The use of claim 1, wherein the treatment of said abnormal cell growth is by inhibiting the activity of PRMT5 proteins in said subject.

3. The use of claim 1 or 2, wherein said abnormal cell growth is cancer.

4. The use of Claim 3, wherein said cancer is selected from the group consisting of lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, and pituitary adenoma.

5. The use of claim 3, wherein said cancer is non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal cancer, endometrial cancer, cervical cancer, bladder cancer, urothelial carcinoma, or pancreatic cancer.

6. The use of any one of claims 1-5, wherein said Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered in a dosage form selected from one or more tablets, one or more capsules, a liquid solution, a liquid suspension, or a syrup.

7. The use of claim 6, wherein said dosage form is one or more tablets.

8. The use of claim 7, wherein said dosage form is a single tablet.

9. The use of any one of claims 1-8, wherein said administration takes place for seven consecutive days.

10. The use of any one of claims 1-8, wherein said administration takes place for one cycle comprising twenty-eight consecutive days.

11. The use of claim 10, wherein said administration takes place for 1-24 cycles.

12. The use of claim 11, wherein said administration takes place for 4 cycles.

13. The use of claim 11, wherein said administration takes place for 6 cycles.

14. The use of claim 11, wherein said administration takes place for 12 cycles.

15. The use of claim 11, wherein said administration takes place for 24 cycles.

16. The use of any one of claims 1-15, wherein said Compound 1 is to be administered to a subject at a dose of about 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, or 150 mg once daily.

17. The use of claim 16, wherein said Compound 1 is to be administered to a subject at a dose of about 4 mg once daily.

18. The use of claim 16, wherein said Compound 1 is to be administered to a subject at a dose of about 6 mg once daily.

19. The use of claim 16, wherein said Compound 1 is to be administered to a subject at a dose of about 8 mg once daily.

20. The use of any one of claims 1-19, wherein the treatment further comprises administration of an effective amount of a second therapeutic agent.

21. The use of claim 20, wherein the second therapeutic agent is a chemotherapeutic agent.

22. The use of claim 21, wherein the chemotherapeutic agent is paclitaxel or docetaxel.

23. The use of claim 20, wherein the second therapeutic agent is an antibody.

24. The use of claim 23, wherein the antibody is a PD-1 or PD-L1 antibody.

25. The use of any one of claims 20-24, wherein the second therapeutic agent is to be administered intravenously, subcutaneously, or orally.

26. The use of any one of claims 20-25, wherein the second therapeutic agent is to be administered to the subject simultaneously with Compound 1.

27. The use of any one of claims 20-25, wherein the second therapeutic agent is to be administered to the subject concurrently with Compound 1.


28. The use of any one of claims 20-25, wherein the second therapeutic agent is to be administered to the subject sequentially with Compound 1.

29. The use of claim 22, wherein docetaxel is to be administered at 75 mg/m^2 intravenously once every 21 days.

30. The use of any one of claims 1-22, wherein the subject is premedicated with a corticosteroid prior to the treatment.

31. The use of any one of claims 3-30, wherein the cancer is relapsed, refractory, or metastatic.


32. A medicament comprising a therapeutically effective amount of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol (Compound 1) having the structure:



,

or a pharmaceutically acceptable salt thereof, for use in the treatment of abnormal cell growth in a subject no more than once per day.

33. A medicament comprising a therapeutically effective amount of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol (Compound 1) having the structure:



,

or a pharmaceutically acceptable salt thereof, and an effective amount of a second therapeutic agent for use in the treatment of abnormal cell growth in a subject no more than once per day.